Loading...
•
Jun 30, 2021
BioCryst Q2 2021 Earnings Report
Reported revenue growth driven by ORLADEYO launch and milestone payment from Torii Pharmaceutical, research and development, and selling, general, and administrative expenses increased, resulting in a net loss.
Key Takeaways
BioCryst announced its Q2 2021 financial results, highlighted by total revenues of $50.0 million, driven by ORLADEYO net revenue of $28.5 million and a $15 million milestone payment from Torii Pharmaceutical. The company's net loss for the quarter was $43.2 million, or $0.24 per share.
Total revenues were $50.0 million, compared to $2.9 million in the second quarter of 2020.
ORLADEYO net revenue was $28.5 million in the second quarter of 2021.
Net loss for the second quarter of 2021 was $43.2 million, or $0.24 per share
Cash, cash equivalents, restricted cash and investments totaled $222.8 million at June 30, 2021.
Forward Guidance
BioCryst is not providing specific revenue or operating expense guidance for the launch period of ORLADEYO. The company believes its current cash runway takes it into 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...